GW4064 is a synthetic agonist of the farnesoid X receptor (FXR), a nuclear receptor involved in the regulation of bile acid, lipid, and glucose metabolism. It is primarily used in research to study FXR signaling pathways and its role in metabolic diseases. Applications include investigating mechanisms in liver disorders such as non-alcoholic fatty liver disease (NAFLD) and cholestasis, where FXR activation helps reduce bile acid toxicity and inflammation. It is also used to explore glucose homeostasis and insulin sensitivity, making it relevant in diabetes research. Additionally, GW4064 helps in understanding the regulation of lipoprotein metabolism and has been used in studies targeting atherosclerosis and other metabolic syndrome-related conditions. Its use remains confined to preclinical research due to lack of clinical development.